Tesamorelin vs Retatrutide: Belly Fat, Weight Loss, and What's Legal
By The RX Index Editorial Team · Last verified October 2026
Tesamorelin vs retatrutide isn't a match between two approved weight-loss shots. Tesamorelin (Egrifta WR) is FDA-approved to reduce deep belly fat in adults with HIV-related lipodystrophy, not for general weight loss. Retatrutide averaged 25% weight loss over 80 weeks in the 12 mg trial group but isn't FDA-approved. Both reduced deep belly fat in studies; neither is a universal winner.
Which one "wins" depends on you: whether you have HIV-related lipodystrophy, whether your goal is belly fat or total weight, and whether you need an approved treatment now.
Here's the catch most stack posts skip. We found no published human study of the two together, and retatrutide has no approved retail product. The side-by-side comes first, followed by the trial and expanded-access options.
RX Index Decision Verdict: Start with the problem you're trying to fix, not the "strongest peptide."
- Best for (tesamorelin): adults with HIV and lipodystrophy whose deep belly fat is the main problem.
- Best for (retatrutide information): adults with obesity asking a study team about trial screening, or a treating doctor about Lilly's narrow expanded-access criteria.
- Not ideal for: anyone shopping for "research use only" vials, a DIY dose, or a stack plan.
- The factor that matters most: whether the evidence and the approved use match the condition you actually have.
Tesamorelin vs retatrutide, side by side
Tesamorelin and retatrutide work through different hormone systems and were tested in different people. Tesamorelin lowered deep belly fat by about 14% to 18% over 26 weeks in adults with HIV-related lipodystrophy, with almost no change in weight. Retatrutide lowered body weight by about 25% on average over 80 weeks in the 12 mg trial group, but it is still an experimental drug.
| Tesamorelin (Egrifta WR) | Retatrutide | |
|---|---|---|
| What it is | A lab-made copy of the brain signal (GHRH) that tells your pituitary gland to release more of your own growth hormone | An experimental weekly shot that acts on three hormone receptors: GLP-1, GIP, and glucagon |
| Is it a GLP-1? | No | GLP-1 is one of its three targets |
| Made by | Theratechnologies | Eli Lilly |
| U.S. status (Oct 15, 2026) | FDA-approved | Not FDA-approved for any use; Lilly plans to apply in early 2027 |
| Approved for | Reducing excess belly fat in adults with HIV who have lipodystrophy. The label says it is not for weight-loss management | Nothing yet |
| How it's given | A shot under the belly skin, once a day | A shot once a week in trials (no approved dose exists) |
| Main measured result | Deep belly fat down 14% to 18% at 26 weeks | Body weight down about 25% at 80 weeks in the 12 mg trial group |
| Effect on the scale | About none | Large |
| Blood sugar | Can raise it | Lowered A1C in trials involving type 2 diabetes |
| Legal way to get it now | A prescription for the brand | A clinical trial, or expanded access your doctor requests |
Sources: FDA Egrifta WR label (revised March 2025); FDA on unapproved GLP-1 drugs; TRIUMPH-1, NEJM 2026; Lilly's TRIUMPH-2 results and filing plan; Lilly Medical's access rules. Checked October 15, 2026.
Two words you'll see a lot below:
- Lipodystrophy is a condition that changes where your body stores fat. In people with HIV, it can pack fat deep in the belly while thinning it elsewhere. Ordinary belly weight gain is not the same diagnosis.
- Visceral fat is the deep fat packed around your organs, inside the belly wall. It's not the fat you can pinch. That's subcutaneous fat, under the skin.
How each one works
Tesamorelin turns up your body's own growth-hormone signal. Growth hormone then raises IGF-1, a growth signal made mostly by the liver, and helps break down deep belly fat. Think of it as a dimmer switch on one hormone, not a whole-body weight-loss tool. FDA label
Retatrutide hits three receptors at once. A receptor is a cell's "mailbox" for a hormone signal. GLP-1 and GIP help control appetite and blood sugar; glucagon signaling can increase energy use. Zepbound (tirzepatide) works on two of those three. Retatrutide study Our triple vs dual agonist guide explains the difference.
What do the fat-loss numbers actually measure?
A drop in visceral fat is not the same measurement as a drop in body weight. Comparing the two percentages without the study's people, time span, and outcome gives the wrong answer. Both drugs lowered deep belly fat in studies, but in very different groups, so these numbers can't crown a winner.
Here's every key number with what it measured attached. The doses shown are study groups, not instructions.
| Study and people | Time and treatment | What was measured | Result | What it does not show |
|---|---|---|---|---|
| Tesamorelin Study 1: adults with HIV and belly-fat buildup | 26 weeks; original Egrifta formulation, 2 mg daily | Visceral-fat area by CT scan | −18% vs +2% on placebo | Not 18% weight loss. Weight changed −0.4 kg vs 0.0 kg |
| Tesamorelin Study 2: same type of patients | 26 weeks; same formulation | Visceral-fat area by CT scan | −14% vs −2% on placebo | Not a result in people without HIV. Weight changed +0.5 kg vs +0.3 kg |
| Retatrutide TRIUMPH-1: 2,339 adults with obesity or overweight, without diabetes | 80 weeks; 12 mg weekly group | Total body weight, treatment-regimen analysis: all randomized participants, including those who stopped treatment | −25.0% vs −3.9% on placebo | Not a comparison with tesamorelin |
| Same trial, different analysis | 80 weeks; same group | Total body weight, efficacy analysis: estimated effect if everyone stayed on assigned treatment | −28.3% vs −2.2% on placebo | Not a second trial. Don't pair it with the other analysis's placebo |
| Retatrutide imaging substudy: 98 adults with obesity or overweight and fatty liver, without type 2 diabetes | 48 weeks; 1, 4, 8, or 12 mg weekly | Visceral-fat volume by MRI | −16.1% to −48.3% across dose groups vs +2.5% on placebo | Not proof it beats tesamorelin. Only 8 to 9 people per group had a week-48 scan, and the authors call the results hypothesis-generating |
Sources: FDA Egrifta WR label, Table 2 and §14; Jastreboff et al., NEJM, Sept 29, 2026; Lilly's TRIUMPH-1 analyses, May 21, 2026; Sanyal et al., Nature Medicine, 2024. The tesamorelin numbers are the label's estimates. The current Egrifta WR (1.28 mg daily) was approved based on matching the original formulation's blood levels; WR and the older SV are not swappable.
Here's how to read that table. Say one report tracks the money in your savings account, and another tracks your whole net worth. A 20% change means very different things in each. Visceral-fat percent and body-weight percent work the same way: different totals, different meaning.
So the honest answer to "which cuts belly fat?" is this. Tesamorelin is the one approved for it, in people with HIV lipodystrophy. Retatrutide also lowered it, along with a lot of total weight, in a small study of people with obesity. We found no published human study putting them side by side.
Looking for general weight-management care rather than HIV-related lipodystrophy treatment? The right GLP-1 provider isn't the same for everyone. It depends on your state, your insurance and formulary (your plan's list of covered drugs), whether you need an FDA-approved or compounded medicine, a shot or a pill, and your budget. Compounded medicines are not FDA-approved and should only be used when an approved drug cannot meet a patient's medical need. FDA guidance Retatrutide is not an approved or compoundable option. Use The RX Index's Find My GLP-1 Path tool to see which fits before you choose. It's free, takes about 2 minutes, and needs no signup.
Belly fat, liver fat, and body weight are different things
Visceral fat sits inside the belly around your organs. Liver fat is fat stored inside the liver itself. Body weight is everything at once. A change in one doesn't tell you the size of a change in another.
Both drugs lowered liver fat, in different people:
| Tesamorelin | Retatrutide | |
|---|---|---|
| Who | 61 adults with HIV and fatty liver | 98 adults with obesity or overweight and fatty liver, no type 2 diabetes |
| How long | 12 months | 48 weeks |
| Liver fat change | 37% placebo-adjusted relative reduction: the difference between each group's change from its starting level | 86% lower from baseline on 12 mg, vs 4.6% lower on placebo |
| Liver fat below the study's 5% threshold | 35% vs 4% on placebo | Estimated 93% on 12 mg, with missing results accounted for statistically |
Sources: Stanley et al., Lancet HIV, 2019; Sanyal et al., Nature Medicine, 2024.
One more thing the label studies showed: tesamorelin's belly-fat drop doesn't stick on its own. In the extension study, people switched from tesamorelin to placebo quickly regained visceral fat. Falutz et al., 2010
Why retatrutide headlines show different percentages
TRIUMPH-1 reported the same trial two ways. "Counting everyone randomized" (−25.0%) includes people who stopped the drug. "If everyone stayed on it" (−28.3%) estimates the effect if everyone stayed on assigned treatment. These are two statistical estimates, each with its own placebo number. Neither is a promise for one person. Trial analyses
Picture a class where some students drop out. One grade counts everyone who enrolled. The other estimates how the class would have done if nobody left. For every trial and dose, see retatrutide results by trial and dose.
Which next step fits your goal?
The real choice usually isn't "tesamorelin or retatrutide." It's whether you need care for a diagnosed fat-distribution condition, general weight-management care, or a research option. This map points each situation to a next step, without guessing anyone's diagnosis.
| Your situation | What to do next | What not to assume |
|---|---|---|
| Diagnosed HIV-related lipodystrophy | Ask your HIV clinician whether tesamorelin fits. Use the maker's THERA support for coverage help | That a weight-loss quiz replaces HIV care |
| General weight goal, no lipodystrophy diagnosis | Talk with a clinician about FDA-approved weight-loss medicines available now | That belly fat on its own means you qualify for tesamorelin's approved use |
| Want to try retatrutide through research | Search Lilly's trial finder and let a study team screen you | That a listed study is enrolling near you, or that you qualify |
| Severe obesity that hasn't responded, plus serious complications | Ask your treating doctor to review Lilly's expanded-access criteria | That a high BMI alone qualifies you |
| Already on a GLP-1, eyeing an add-on | Bring the goal and any results you already have to your current prescriber | That a different mechanism makes a stack safe or better |
| Not sure if it's weight, fat placement, or something else | Start with an assessment, not a drug | That "unknown" means yes, or no |
Before you choose, three quick questions to ask yourself:
- Am I trying to shrink deep belly fat, lower my total weight, or both?
- Has a doctor diagnosed HIV-related lipodystrophy?
- Is my BMI 30 or higher, or 27 or higher with a weight-related condition like high blood pressure? (Not sure? Check our BMI eligibility chart. These common starting thresholds do not establish that a medicine is right for you.)
If you answered "total weight" and "no" to the second question, ask a clinician whether an approved weight-loss medicine fits.
Can you take them together, and will tesamorelin protect your muscle?
We found no published human study showing that tesamorelin and retatrutide together are safe or work better. Their separate blood-sugar results do not establish what happens when they are combined. Retatrutide access is limited to trials or narrow, physician-led expanded access—not a retail "stack." FDA; Lilly Medical
Our October 15, 2026 searches of published research and indexed trial records found no human trial of the two drugs together. Different mechanisms are a reason a researcher might ask the question. They aren't an answer.
The blood-sugar problem
Tesamorelin can push blood sugar up. In its 26-week trials, 5% of people on tesamorelin reached a diabetes-range A1C (6.5% or higher) vs 1% on placebo. A1C is a test of average blood sugar. Some participants already had diet-controlled type 2 diabetes. FDA label
Retatrutide lowered blood sugar in people with type 2 diabetes. In TRIUMPH-2, A1C fell 1.5 percentage points on 12 mg vs 0.2 on placebo over 80 weeks in Lilly's efficacy analysis. Lilly's TRIUMPH-2 results; our trial tracker
To be fair, a separate 12-week study of tesamorelin in people with type 2 diabetes found no significant difference in blood-sugar control from placebo at the end of treatment. A temporary fasting-glucose rise appeared earlier in the higher-dose group. Clemmons et al., 2017 That does not erase the FDA warning or show that the two drugs cancel each other out. That's a monitoring job for a clinician, not a guess.
The muscle question
"Keep my gym gains" is the worry behind a lot of these searches. We found no published human trial showing that tesamorelin protects muscle during retatrutide or other GLP-1 weight loss. A theory about growth hormone isn't the same as proof in people taking both.
Retatrutide itself has body-composition data. A 36-week study in adults with type 2 diabetes measured fat and lean mass; its authors reported lean-mass loss alongside weight loss, not complete muscle protection. It did not test tesamorelin. Coskun et al., 2025
Also, "lean mass" on a body scan isn't only muscle. It includes water and organs too. For what GLP-1 studies actually measure, see what GLP-1 body-composition studies measure and our guide to muscle loss on GLP-1s. Enough protein, strength training, and checks on muscle strength are the basics recommended in joint GLP-1 nutrition guidance.
If a clinic offered you a "Reta + Tesa" plan
Ask these before you pay anything:
- Is this brand Egrifta WR from a specialty pharmacy, or something mixed elsewhere?
- Where does the retatrutide come from? (It has no approved retail product; legitimate access requires a trial or the physician-led expanded-access process.)
- Who checks my blood sugar and IGF-1, and how often?
- Who do I call if I have a reaction?
If the answers are vague, that tells you what you need to know. Don't add, combine, or switch medicines based on this page. Bring it to the prescriber who knows your history.
Which risks matter before you choose?
Tesamorelin has an FDA label with specific warnings and clear reasons not to use it. Retatrutide's safety results discussed here come from trials; it has no approved label yet. The risks are different, not just bigger or smaller.
| Source | What to know | What it means for you |
|---|---|---|
| Tesamorelin FDA label: who shouldn't use it | Pregnancy; active cancer; disruption of the hypothalamic-pituitary system, which controls growth-hormone release (for example, after pituitary surgery, a pituitary tumor, head radiation, or head injury); allergy to tesamorelin or its ingredients | A contraindication is a reason the label says not to use a drug. A clinician has to check these first |
| Tesamorelin FDA label: warnings | Higher IGF-1; fluid retention; higher blood sugar; allergic reactions; injection-site reactions; concern about cancer growth or recurrence. The critical-illness warning is based on deaths reported with high-dose growth hormone, not a tesamorelin death rate. Long-term heart and blood-vessel safety is not established | Your clinician tracks these with labs and check-ins. "It boosts a natural hormone" doesn't make it risk-free |
| Tesamorelin FDA label: common side effects (26 weeks) | Injection-site reactions 17% vs 6% on placebo; muscle aches 6% vs 2%; leg or ankle swelling 6% vs 2%; joint pain 13% vs 11% | These rates describe the named events in the label's Table 1, not every possible reaction |
| Retatrutide TRIUMPH-1 (Lilly-reported, 12 mg, 80 weeks) | Nausea 42.4% vs 14.8%; a tingling or burning skin feeling (dysesthesia) 12.5% vs 0.9%; 11.3% stopped because of side effects vs 4.9% on placebo | Stomach effects were the most common. These are trial observations, not a label |
| Unapproved online products | FDA says retatrutide can't be compounded and has warned sellers of "research use only" vials sold for people | A research label is not FDA approval. FDA has not reviewed these products for safety, effectiveness, or quality |
Sources: FDA Egrifta WR label; Lilly TRIUMPH-1 results, May 21, 2026; FDA on unapproved GLP-1 drugs. More detail: retatrutide side effects in the trials.
Get urgent help: Trouble breathing, or swelling of the face or throat after a shot, needs emergency care: call 911. If you used an unapproved or unknown vial labeled retatrutide or tesamorelin and feel unwell, call Poison Control at 1-800-222-1222. For a non-emergency problem with prescribed Egrifta WR, contact your prescriber.
If you're under 18, pregnant or planning a pregnancy, have type 1 diabetes, or have a history of an eating disorder, start with your own clinician before any program. Our GLP-1 hard contraindications guide covers the approved weight-loss drugs.
What can you get now, and what will it cost?
Tesamorelin is available as an approved prescription brand, but its approved use is narrow and your cost needs a pharmacy and benefits check. Retatrutide access is through trials or Lilly's expanded-access program, which your doctor must request. FDA says retatrutide cannot be compounded; tesamorelin is outside the federal pharmacy-compounding exemptions.
| Route | Tesamorelin | Retatrutide |
|---|---|---|
| Brand prescription | Yes: Egrifta WR. Your plan can require prior authorization (a permission slip from your insurer before it pays); THERA can check | Not possible; not approved |
| Off-label prescription | A doctor may legally prescribe an approved drug for another use. Ask your plan whether it covers that use | Not possible; there's no approved drug to prescribe |
| Clinical trial | — | Yes, if you qualify and a site is enrolling |
| Expanded access | — | Doctor-requested, with strict criteria (below) |
| Compounded | Not eligible for the usual pharmacy-compounding exemptions. Egrifta and Egrifta SV transitioned to biologic licenses on March 23, 2020; biological products do not qualify under sections 503A or 503B | Not allowed. FDA says retatrutide can't be used in compounding under federal law |
| "Research use only" vials | Not for human use | Not for human use. FDA has warned sellers; Lilly announced six lawsuits against sellers on Aug 12, 2026 |
Sources: FDA list of products deemed biologics, March 23, 2020; FDA notice to compounders; FDA on unapproved GLP-1 drugs; FDA on off-label use. Checked October 15, 2026.
That's why an ad for "compounded tesamorelin" is not the same as an Egrifta prescription. It does not qualify for the federal exemptions that allow ordinary pharmacy compounding. FDA has separate rules for mixing, diluting, or repackaging an approved biologic; that does not authorize making a new tesamorelin product from bulk powder.
What tesamorelin costs
We could not verify a current cash price from the manufacturer or a dispensing pharmacy on October 15, 2026. Egrifta WR comes as four vials, each holding seven daily doses, so a box covers 28 days—not a calendar month. Ask the specialty pharmacy for a quote for that exact box, plus any separate injection-supply charges. Visits and monitoring tests also need a cost check. FDA label, §16; maker's approval release
If you have HIV-related lipodystrophy, your real cost depends on your plan. The maker's THERA program offers co-pay help for people with commercial insurance, resources for people with government insurance, and a patient assistance program that gives qualifying patients the medicine at no cost. We couldn't confirm a typical out-of-pocket price, because it depends on your plan and pharmacy. THERA patient support
Already prescribed Egrifta WR and stuck on coverage or cost? THERA's coordinators handle benefits checks and assistance (1-833-23-THERA).
What retatrutide costs
There is no approved commercial retatrutide price to compare. Lilly says it provides retatrutide at no cost through its expanded-access program. That covers the medicine only; doctor visits, labs, and other care may still cost money. Lilly Medical For price guesses after approval and why they're only guesses, see retatrutide cost predictions.
Retatrutide's two legal doors: trials and expanded access
Trials. On October 15, 2026, Lilly's trial finder listed SYNERGY-Outcomes, a fatty-liver study involving retatrutide and tirzepatide, as enrolling. That is a disease-specific study, not general access for anyone who wants to lose weight. A study team decides who qualifies and whether a nearby site is screening. Our retatrutide clinical trials tracker collects study records and their dated statuses; check the official listing for changes.
Want to see whether a study might fit? Search the listing, then ask the study team about screening.
Search Lilly's clinical trials
Expanded access. This is a rare path for very sick patients who can't join a trial. Lilly's page (last reviewed August 26, 2026) says a person must meet all of these:
- 18 or older.
- BMI of 35 or higher, even after sticking with and tolerating the highest available dose of a long-term weight-loss medicine.
- Two or more serious or life-threatening obesity-related conditions, currently being treated.
- Can't join a retatrutide trial, or a similar one, because they don't qualify or no site is reasonably close.
- All standard options, including weight-loss surgery, discussed with them.
A medical reason not to take retatrutide rules a person out. Your treating doctor makes the request; Lilly asks patients not to call directly. If approved, the doctor has to file with FDA, get ethics-board approval, and store and hand out the drug. Lilly doesn't ship to patients. Availability also depends on location, supply, and a case-by-case review. Lilly Medical
Say you're 52, your BMI is 41, and you have sleep apnea and heart disease despite a year on the top dose of Zepbound. Those details alone do not establish eligibility: both complications must meet the program's severity criteria, and every other condition above must also be met. Your doctor is the one who can find out.
Read Lilly's expanded-access criteria
More on both doors: current retatrutide access pathways.
The approved options you can discuss now
Here's the honest limit: this page cannot get you a retatrutide prescription. What you can do now is talk with a clinician about FDA-approved weight-loss medicines. That includes tirzepatide (Zepbound), which hits two of retatrutide's three targets and is the drug retatrutide is being tested against in TRIUMPH-5. There are approved pills too; see our guide to the best FDA-approved GLP-1 pill.
If you've settled on wanting an FDA-approved weight-management option, Ro is one place to start. Its clinicians can prescribe Zepbound, Wegovy, and the Foundayo and Wegovy pills when they fit. Ro also lists Ozempic, which is FDA-approved for type 2 diabetes and related indications—not weight-loss management. Ro's published weight-loss menu does not list tesamorelin or retatrutide. Ro's offerings; Ozempic's approved uses
Ro's membership on October 15, 2026:
- $39 for the first month.
- After that, $149 month to month. Prepaying lowers the monthly rate: $99 a month for 3 months means $297 up front; $89 for 6 means $534 up front; $74 for 12 means $888 up front. These are membership charges after the introductory month, not all-in medication prices.
- Medication is billed separately from the membership.
- Ro says it refunds the $39 if you're not eligible for a GLP-1.
The membership includes clinician support and lab testing when ordered as part of the program. Ro's terms cap included medical consults at 24 per year, then charge $15 each; additional lab tests can cost extra. Membership renews automatically. Once paid, the ongoing membership fee is non-refundable; cancel at least 48 hours before renewal to stop the next charge. Check the amount and billing interval at checkout. Ro's membership terms
On Medicare, Medicaid, or TRICARE? Start with your own plan and clinician; those programs have their own rules. Paying cash and comparing prices? See the cheapest Zepbound without insurance.
Ready to review clinician-led options and the current terms—not a retatrutide offer?
See Ro's FDA-approved GLP-1 options
What we actually verified
We read the FDA label, FDA's own pages on compounding and unapproved GLP-1 drugs, the original studies listed below, and Lilly's access rules. We did not test either drug or check anyone's eligibility. Here's exactly what we checked and what we couldn't.
Last verified October 2026. Source checks completed October 15, 2026:
- FDA's Egrifta WR label (revised March 2025), including the clinical tables: approved use, formulation, who shouldn't use it, warnings, side effects, and the visceral-fat and weight results.
- FDA's list of products that transitioned to biologic licenses on March 23, 2020, its compounding notice, and its page on unapproved GLP-1 drugs.
- The full retatrutide imaging study (Nature Medicine, 2024), tesamorelin liver study (Lancet HIV, 2019), and tesamorelin diabetes study (2017); the 2010 extension-study abstract and the 2025 retatrutide body-composition abstract.
- The published TRIUMPH-1 abstract and Lilly's May 21, 2026 results release. The retatrutide side-effect percentages here are Lilly-reported, not independently rechecked against the full journal safety table. We also read Lilly's September 29, 2026 TRIUMPH-2 release and filing plan.
- Lilly Medical's expanded-access page (last reviewed August 26, 2026), Lilly's current trial finder and TRIUMPH-5 study page, and its August 12, 2026 announcement of lawsuits. Our linked trial tracker separately labels its October 14, 2026 snapshot; this page reports the sponsor listings checked October 15.
- The THERA patient support page, Ro's pricing and membership terms, the manufacturer's Egrifta WR packaging information, and the official sources for the approved-pill and nutrition statements.
What we couldn't confirm: a current manufacturer or dispensing-pharmacy cash quote or typical insured price for Egrifta WR; an approved commercial retatrutide price; a published human study of the two drugs together; or what a specific clinic's "tesamorelin" contains. Trial openings here are named sponsor listings, not a complete list of all recruiting studies. Ro's terms and Lilly's access rules are what those companies publish. We didn't enroll, complete a paid checkout, or check anyone's coverage. No physician reviewed this version.
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.
We didn't give either drug a score; see our methodology for how we rate providers and paths. Found an error? Our corrections page explains how we fix it.
Tesamorelin vs retatrutide FAQ
Which is better for belly fat?
Tesamorelin is the one FDA-approved for deep belly fat, but only in adults with HIV-related lipodystrophy. In that group it cut visceral fat 14% to 18% in 26 weeks. Retatrutide also lowered visceral fat in a small study of people with obesity, with far more total weight loss. We found no direct human comparison, so your diagnosis decides more than either headline number. FDA label; retatrutide imaging study
Can I take tesamorelin and retatrutide together?
We found no published human study establishing the combination's safety or benefit. Tesamorelin can raise blood sugar, while retatrutide lowered A1C in diabetes trials; that does not prove the effects cancel out. Retatrutide access is through trials or narrow physician-led expanded access. FDA label; Lilly Medical
Will tesamorelin help me keep muscle while on retatrutide?
We found no published human trial showing that it does. Protein, strength training, and checks on muscle strength are recommended in joint GLP-1 nutrition guidance; that is not evidence for adding tesamorelin.
Will tesamorelin interfere with retatrutide weight loss?
We found no published human study that answers that question. On its own, tesamorelin produced almost no average weight change in its label trials. Its blood-sugar and IGF-1 effects are reasons for clinician monitoring, not evidence that it helps or hinders retatrutide weight loss. FDA label
Is tesamorelin a GLP-1?
No. Tesamorelin copies GHRH, the signal that releases growth hormone. It works through growth hormone, not the appetite hormones GLP-1 drugs use.
Is retatrutide FDA-approved? When will it be?
No, it isn't approved for any use. Lilly says it plans to apply in the first quarter of 2027. FDA review comes after that, and there's no confirmed approval or launch date. FDA status; Lilly's filing plan
Is compounded tesamorelin legal?
Egrifta and Egrifta SV transitioned to biologic licenses on March 23, 2020. FDA says biological products do not qualify for the federal 503A or 503B exemptions that allow ordinary pharmacy compounding. Products sold as "compounded tesamorelin" are outside that pathway. FDA notice
Can a doctor prescribe tesamorelin off-label?
A licensed doctor can legally prescribe an approved drug for a use that isn't on its label. That doesn't mean FDA approved that use; ask your plan whether it covers it. It also doesn't make an unapproved online vial the same as Egrifta WR. FDA on off-label use
How much does tesamorelin cost?
We could not verify a current manufacturer or dispensing-pharmacy cash quote on October 15, 2026. Ask for a quote for the 28-day Egrifta WR box and a separate benefits check. The maker's THERA program offers co-pay help and a no-cost medicine program for qualifying patients.
Can I get retatrutide outside a clinical trial?
Lilly describes a narrow expanded-access program that your treating doctor must request. All five criteria above must be met, including BMI of at least 35 despite adherence to and tolerance of the highest available dose of a chronic weight-management treatment, plus at least two serious or life-threatening obesity-related complications under treatment. Lilly supplies the medicine without charge; other care costs still need checking, and eligibility is assessed individually. Lilly Medical
Do I have to use a shot for weight-loss care?
No. FDA-approved GLP-1 pills exist for qualifying adults; Foundayo is one example. They're different drugs from both of these, so a clinician decides whether one fits.
Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.
Sources
- U.S. FDA. EGRIFTA WR (tesamorelin) prescribing information, revised March 2025. Checked October 15, 2026.
- U.S. FDA. List of approved NDAs for biological products deemed to be BLAs on March 23, 2020. Checked October 15, 2026.
- U.S. FDA. Notice to compounders: changes that affect compounding on March 23, 2020. Checked October 15, 2026.
- U.S. FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Checked October 15, 2026.
- U.S. FDA. Understanding unapproved use of approved drugs "off label". Checked October 15, 2026.
- Theratechnologies. FDA approval of EGRIFTA WR, March 25, 2025. Checked October 15, 2026.
- Falutz J, et al. Tesamorelin in HIV-infected patients with abdominal fat accumulation, with safety extension. J Acquir Immune Defic Syndr, 2010. Abstract checked October 15, 2026.
- Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. Lancet HIV, 2019. Full text checked October 15, 2026.
- Clemmons DR, et al. Safety and metabolic effects of tesamorelin in type 2 diabetes. PLoS One, 2017. Full text checked October 15, 2026.
- Jastreboff AM, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. NEJM, published September 29, 2026. Published abstract checked October 15, 2026; the side-effect rates on this page are sourced to Lilly’s release.
- Eli Lilly. TRIUMPH-1 results, May 21, 2026. Full release checked October 15, 2026; source of the labeled sponsor-reported adverse-event rates and efficacy analysis.
- Sanyal AJ, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 2024. Checked October 15, 2026.
- Lilly Medical. Is there an expanded access program for retatrutide? Last reviewed August 26, 2026. Checked October 15, 2026.
- Eli Lilly. Clinical trial finder. Checked October 15, 2026.
- THERA patient support. EGRIFTA WR patient support. Checked October 15, 2026.
- Ro. Body Membership Terms and Conditions, §4; page revised April 2, 2026. Checked October 15, 2026.
- Ro. Weight loss program pricing. Checked October 15, 2026.
- Eli Lilly. TRIUMPH-2 results and planned first-quarter 2027 filing, September 29, 2026. Company-authored release distributed by PR Newswire; full text checked October 15, 2026.
- Eli Lilly. Announcement of six lawsuits concerning unapproved retatrutide sales, August 12, 2026. Checked October 15, 2026; announcement of filings, not a finding that Lilly won the cases.
- American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society. Nutritional priorities to support GLP-1 therapy for obesity, May 2025 joint advisory. Official society summary checked October 15, 2026.
- U.S. FDA. Foundayo (orforglipron) approval, April 1, 2026. Checked October 15, 2026.
- Novo Nordisk. Ozempic approved uses and safety information. Checked October 15, 2026.
- National Capital Poison Center. Poison Control help and emergency instructions. Checked October 15, 2026.
- Eli Lilly. TRIUMPH-5 study page, NCT06662383. Study purpose and completed-enrollment label checked October 15, 2026.
- Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes. Lancet Diabetes & Endocrinology, published online June 30, 2025. Original abstract checked October 15, 2026; qualitative findings only, no numerical muscle-loss claim.